HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval
HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.
HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.
In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.
Rosenthal is a lymphoma specialist. “Would you like to have a bone marrow biopsy today or tomorrow?” These are the only words I remember coming